|Table of Contents|

Expression of human mitochondrial transcription termination factor 3 in human breast cancer tissues and its clinical significance

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 21
Page:
3956-3962
Research Field:
Publishing date:

Info

Title:
Expression of human mitochondrial transcription termination factor 3 in human breast cancer tissues and its clinical significance
Author(s):
LIU Ruai1; 2; WANG Boyong1; 2; LIN Yaru1; 2; ZI Jiaji1; 2; YAN Changbao3; DAI Liping3; YU Min4; XIONG Wei1; 2
1.Department of Biochemistry and Molecular Biology,College of Basic Medical Sciences，Dali University,Yunnan Dali 671000,China; 2.Yunnan Provincial Key Laboratory of Entomological Biopharmaceutical R&D,College of Pharmacy,Dali University,Yunnan Dali 671000,China; 3.Department of Pathology,First People’s Hospital of Dali Bai Autonomous Prefecture,Yunnan Dali 671000,China; 4.Laboratory of Biochemistry and Molecular Biology,College of Life Sciences,Yunnan University,Yunnan Kunming 650091,China.
Keywords:
mitochondrial transcription termination factor 3; breast cancer; immunohistochemistry; TCGA dataset; prognosis
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.21.010
Abstract:
Objective:To elucidate the expression of mitochondrial transcription termination factor 3(MTERF3) in breast cancer and its correlation with the clinicopathological characteristics and prognosis of patients.Methods:The expression levels of MTERF3 protein in 58 breast cancer tissues and paired paracancerous tissues were examined using the immunohistochemical SP method.The MTERF3 mRNA expression dataset,clinicopathological information and prognostic information of 705 breast cancer patients in The Cancer Genome Atlas(TCGA) database were obtained by R 4.2.0 software,and the correlation between MTERF3 expression and clinicopathological parameters of breast cancer patients was differentially analysed and visualised using the UALCAN database for visual analysis.Overall survival of patients and disease-free progression survival were calculated using the Kaplan-Meier method and Cox regression analysised clinicopathological factors affecting the prognosis of breast cancer patients.Results:MTERF3 protein was mainly expressed in the cytoplasm,and the positive expression rate in breast cancer tissues(91.38%) was significantly higher than that in breast cancer paracancer tissues(20.69%),with a significant difference in the positive rate between the two groups(P<0.01).The TCGA dataset study showed that MTERF3 was significantly correlated with ER status,PR status,breast cancer molecular staging,cancer type,histological diagnosis,and primary site of breast cancer patients(P<0.05).But not with patients’ age,gender,T-stage,N-stage,M-stage,AJCC pathological stage,HER2 status and history of malignancy.MTERF3 was not associated with overall survival time and disease-free survival time in breast cancer patients(P>0.05).Cox multifactorial analysis suggested that age,M stage and type of pathology may be independent risk factors for poor prognosis in breast cancer patients(P<0.05).Conclusion:The positive rate and expression of MTERF3 protein were significantly increased in breast cancer tissues,suggesting that MTERF3 may be closely related to the process of breast cancer development,and this gene is expected to be a potential gene target for clinical diagnosis and treatment of breast cancer patients.

References:

［1］ SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］ 中华人民共和国国家卫生健康委员会.乳腺癌诊疗指南（2022年版）［J］.中国合理用药探索,2022,19(10):1-26.National Health Commission of The People’s Republic of China.Breast cancer diagnosis and treatment guidelines(2022 edition) ［J］.Chinese Journal of Rational Drug Use,2022,19(10):1-26.
［3］ ZHU S,XU N,HAN Y,et al.MTERF3 contributes to MPP+-induced mitochondrial dysfunction in SH-SY5Y cells［J］.Acta Biochim Biophys Sin(Shanghai),2022,54(8):1113-1121.
［4］ ANDERSSON DC,FAUCONNIER J,PARK CB,et al.Enhanced cardiomyocyte Ca(2+) cycling precedes terminal AV-block in mitochondrial cardiomyopathy Mterf3 KO mice［J］.Antioxid Redox Signal,2011,15(9):2455-2464.
［5］ 熊伟,余敏,左绍远.线粒体转录终止因子蛋白家族在线粒体基因表达中的调节作用［J］.中国生物化学与分子生物学报,2015,31(3):223-231.XIONG W,YU M,ZUO SY.Regulation of mitochondrial transcription termination factor protein family in mitochondrial gene expression［J］.Chinese Journal of Biochemistry and Molecular Biology,2015,31(3):223-231.
［6］ ROBERTI M,POLOSA PL,BRUNI F,et al.MTERF factors:a multifunction protein family［J］.Biomol Concepts,2010,1(2):215-224.
［7］ PARK CB,ASIN-CAYUELA J,CMARA Y,et al.MTERF3 is a negative regulator of mammalian mtDNA transcription［J］.Cell,2007,130(2):273-285.
［8］ ROBERTI M,POLOSA PL,BRUNI F,et al.The MTERF family proteins:mitochondrial transcription regulators and beyond［J］.Biochim Biophys Acta,2009,1787(5):303-311.
［9］ ROBERTI M,BRUNI F,LOGUERCIO POLOSA P,et al.MTERF3,the most conserved member of the mTERF-family,is a modular factor involved in mitochondrial protein synthesis［J］.Biochim Biophys Acta,2006,1757(10):1199-1206.
［10］ WREDENBERG A,LAGOUGE M,BRATIC A,et al.MTERF3 regulates mitochondrial ribosome biogenesis in invertebrates and mammals［J］.PLoS Genet,2013,9(1):e1003178.
［11］ ZI J,WANG W,SUN M,et al.A high expression of MTERF3 correlates with tumor progression and predicts poor outcomes in patients with brain glioma［J］.Int J Clin Exp Pathol,2019,12(5):1909-1920.
［12］ 孙美涛,梅雯,王唯斯,等.MTERF3过表达对脑胶质瘤U251细胞线粒体基因表达及细胞增殖和迁移的影响［J］.实用医药杂志,2019,36(5):454-459.SUN MT,MEI W,WANG WS,et al.The effect of MTERF3 overexpression on mitochondrial gene expression,cell proliferation and migration in glioma U251 cells［J］.Practical Journal of Medicine & Pharmacy,2019,36(5):454-459.
［13］ 孙美涛,赵恒宇,李晓燕,等.线粒体转录终止因子3在甲状腺癌中的表达及预后意义［J］.井冈山大学学报(自然科学版),2022,43(5):36-43.SUN MT,ZHAO HY,LI XY,et al.Expression and prognostic significance of mitochondrial transcription termination factor 3 in thyroid carcinoma［J］.Journal of Jinggangshan University(Natural　Sciences Edition),2022,43(5):36-43.
［14］ 自加吉,杨勇琴,孙美涛,等.非小细胞肺癌中人线粒体转录终止因子3蛋白的表达及临床病理学意义［J］.医学研究生学报,2017,30(2):160-164.ZI JJ,YANG YQ,SUN MT,et al.Expression of human mitochondrial transcription termination factor 3 protein in non-small cell lung cancer and its clinicopathological significance［J］.Journal of Medical Postgraduates,2017，30(2):160-164.
［15］ 自加吉,杨勇琴,孙美涛,等.人线粒体转录终止因子3在胃癌组织中的表达及其意义［J］.临床与实验病理学杂志,2017,33(1):84-87.ZI JJ,YANG YQ,SUN MT,et al.Expression and significance of human mitochondrial transcription termination factor 3 in gastric cancer tissues［J］.Chinese Journal of Clinical and Experimental Pathology,2017,33(1):84-87.
［16］ 自加吉,李彬,王唯斯,等.基于数据挖掘分析MTERF3基因在肝细胞癌的表达及预后意义［J］.生物技术,2018,28(5):484-491.ZI JJ,LI B,WANG WS,et al.To analyze the expression and prognostic significance of MTERF3 gene in hepatocellular carcinoma based on data mining［J］.Biotechnology,2018,28(5):484-491.
［17］ 梅雯,自加吉,孙美涛,等.基于ONCOMINE和TCGA数据库分析人MTERF3在子宫颈癌中的表达及预后意义［J］.井冈山大学学报(自然科学版),2018,39(1):43-47.MEI W,ZI JJ,SUN MT,et al.To analyze the expression and prognostic significance of human MTERF3 in cervical cancer based on ONCOMINE and TCGA database［J］.Journal of Jinggangshan University(Natural　Sciences Edition),2018,39(1):43-47.
［18］ 熊伟,杨勇琴,李彬,等.hMTERF3基因在卵巢癌组织的表达及其对预后的影响［J］.实用医药杂志,2018,35(5):428-433.XIONG W,YANG YQ,LI B,et al.Expression of hMTERF3 gene in ovarian cancer and its effect on prognosis［J］.Practical Journal of Medicine & Pharmacy,2018,35(5):428-433.
［19］ 梅雯,孙美涛,王唯斯,等.利用Oncomine和TCGA数据集分析MTERF3在大肠腺癌的表达及预后作用［J］.齐齐哈尔医学院学报,2018,39(8):869-873.MEI W,SUN MT,WANG WS,et al.Oncomine and TCGA datasets were used to analyze the expression and prognostic role of MTERF3 in colorectal adenocarcinoma［J］.Journal of Qiqihar Medical College,2018,39(8):869-873.
［20］ 刘瑶,贺兴波,郑弘毅,等.线粒体质量控制失调与恶性肿瘤发生和发展相关性的研究进展［J］.生物化学与生物物理进展,2018,45(5):501-511.LIU Y,HE XB,ZHENG HY,et al.Research progress on the correlation between mitochondrial quality control disorder and the occurrence and development of malignant tumors［J］.Advances in Biochemistry and Biophysics,2018,45(5):501-511.
［21］ 谭秋芬,胡惠军.FEN1、GTF2IP23、KDM4A在乳腺癌组织中的表达研究［J］.国际检验医学杂志,2023,44(03):311-315.TAN QF,HU HJ.The expression of FEN1,GTF2IP23 and KDM4A in breast cancer tissues［J］.International Journal of Laboratory Medicine,2023,44(03):311-315.
［22］ PEROU CM,SRLIE T,EISEN MB,et al.Molecular portraits of human breast tumours［J］.Nature,2000,406(6797):747-752.
［23］ 何思怡,李贺,曹毛毛,等.全球及我国女性乳腺癌疾病负担年龄分布及变化趋势［J］.中国肿瘤,2023,32(01):1-7.HE SY,LI H,CAO MM,et al.Age distribution and change trend of breast cancer disease burden in global and Chinese women［J］.China Cancer,2023,32(01):1-7.
［24］ GIULIANO AE,EDGE SB,HORTOBAGYI GN.Eighth edition of the AJCC cancer staging manual:breast cancer［J］.Ann Surg Oncol,2018,25(7):1783-1785.
［25］ LIU Y,CHEN C,WANG X,et al.An epigenetic role of mitochondria in cancer［J］.Cells,2022,11(16):2518.
［26］ BADRINATH N,YOO SY.Mitochondria in cancer:in the aspects of tumorigenesis and targeted therapy［J］.Carcinogenesis,2018,39(12):1419-1430.
［27］ CHAKRABARTY S,GOVINDARAJ P,SANKARAN BP,et al.Contribution of nuclear and mitochondrial gene mutations in mitochondrial encephalopathy,lactic acidosis,and stroke-like episodes(MELAS) syndrome［J］.J Neurol,2021,268(6):2192-2207.
［28］ MALIK N,KIM YI,YAN H,et al.Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer［J］.Cancer Res,2023,83(8):1280-1298.
［29］ PREZ-AMADO CJ,TOVAR H,GMEZ-ROMERO L,et al.Mitochondrial DNA mutation analysis in breast cancer:shifting from germline heteroplasmy toward homoplasmy in tumors［J］.Front Oncol,2020,10:572954.
［30］ 徐冰洁,何昌龙,赵静，等.线粒体功能紊乱与肿瘤［J］.现代肿瘤医学,2018,26(05):772-776.XU BJ,HE CL,ZHAO J,et al.Mitochondrial dysfunction in tumor［J］.Modern Oncology,2018,26(05):772-776.
［31］ LIU X,CAO X,LIU C,et al.MTERFD1 promotes cell growth and irradiation resistance in colorectal cancer by upregulating interleukin-6 and interleukin-11［J］.Int J Biol Sci,2019,15(12):2750-2762.
［32］ SHAHBANDI A,NGUYEN HD,JACKSON JG.TP53 mutations and outcomes in breast cancer:reading beyond the headlines［J］.Trends Cancer,2020,6(2):98-110.

Memo

Memo:
National Natural Science Foundation of China(No.82160516，32160167）；国家自然科学基金（编号：82160516，32160167）；云南省应用基础研究专项面上项目（编号：202201AT070004，202301AT070023）；云南省地方本科高校基础研究联合专项面上项目（编号：202101BA070001-226）；云南省高校地方本科高校基础研究联合专项青年项目（编号：202101BA070001-282）；云南省昆虫生物医药研发重点实验
Last Update: 2023-09-28